Does family-centred education improve treatment adherence, glycosylated haemoglobin and blood glucose level in patients with type 1 diabetes? A randomized clinical trial.

AIM: To investigate the effect of family-centred education on treatment adherence, glycosylated haemoglobin and blood glucose level in patients with Type 1 Diabetes Mellitus. DESIGN: Randomized controlled trial. METHODS: Sixty patients with Type 1 Diabetes Mellitus were randomly allocated into the intervention and control group. Data were collected using demographic and Modanloo Adherence to Treatment Questionnaires. The patients received 12 family-centred educational sessions in the intervention group. RESULTS: A significant difference was found in the mean score of treatment adherence between the two groups after the intervention (p < 0.001). The mean score of treatment adherence significantly increased in the intervention group after family-centred education. The mean score of Fasting Blood Glucose and Glycosylated Haemoglobin A1C significantly decreased in the intervention group after the intervention (p < 0.001). CONCLUSION: Relevant authorities need to consider family-centred education as one of the most important education methods in Type 1 Diabetes Mellitus patients. TRIAL REGISTRATION: IRCT20131112015390N4; August 21, 2020.

Early pregnancy glycaemia predicts postpartum diabetes mellitus.

OBJECTIVE: To determine the association between early pregnancy glycaemia, as measured by glycosylated haemoglobin A1c (HbA1c) at the first prenatal visit, and persistent postpartum diabetes mellitus (DM). STUDY DESIGN: All women first diagnosed with DM during pregnancy who had both HbA1c prior to 24 weeks and postpartum DM testing were included. The proportions of women with normal (<5.7%), prediabetic (5.7-6.4%) and elevated (≥6.5%) early HbA1c who tested positive for postpartum DM were compared. Test characteristics of HbA1c to predict persistent postpartum DM were calculated. RESULTS: One hundred and twenty-one women met the study inclusion criteria. HbA1c was obtained at a median gestational age of 9 weeks. Twenty-two women (18.2%) had persistent postpartum DM, which was highly correlated with early HbA1c: 16 (73%) women had an elevated HbA1c, five (22.7%) women had a prediabetic HbA1c and only one (4.5%) woman had a normal HbA1c. Of 65 women with gestational DM and a normal early HbA1c, only one (1.5%) had persistent DM within the first year (negative predictive value 98.5%). Sixteen of 18 women with an elevated early HbA1c had persistent postpartum DM (positive predictive value 88.9%). These percentages were significant overall and between groups (p < 0.001). No clinical or demographic factors were highly predictive of postpartum DM. CONCLUSIONS: Early pregnancy glycaemia, as measured by HbA1c at the first prenatal visit, is highly predictive of persistent postpartum DM, and may allow clinically important risk stratification to prioritize postpartum testing and care. Postpartum DM is rare amongst women with gestational DM who begin the pregnancy with a normal HbA1c, while postpartum DM is highly likely for those with an elevated HbA1c in early pregnancy. Nearly three-quarters of women who tested positive for DM post partum had an elevated HbA1c in early pregnancy, indicating that they had undiagnosed DM prior to conception.

Sleep quality in people with type 2 diabetes controlled at the primary level and its association with sociodemographic and clinical characteristics.

Type 2 diabetes (DM2) is one of the diseases that cause the highest premature mortality and disability worldwide. Sleep disturbances have been associated with the onset of metabolic disorders and increased levels of glycated haemoglobin in diabetics. OBJECTIVE: To evaluate the quality of sleep of people with type 2 diabetes and its association with sociodemographic, clinical, and metabolic characteristics. METHODS: Observational, cross-sectional, analytical study of 223 patients with DM2 between 20 and 64 years old, controlled in a primary health care centre in Chile. RESULTS: Most were women (66.4%), average age 54.7 years. Only 33% slept the required number of hours (7-9 h) to maintain health. Fifty-seven point seven percent were metabolically unbalanced (Hb1Ac > 7%). Seventy-five point two percent presented sleep problems of varying severity, which were associated with being a woman, night pain, nocturia, time of diagnosis of diabetes, and depressive symptoms. Persons with poor sleep quality were 73% more likely to be metabolically decompensated, however, this result was not statistically significant: OR = 1.73 (CI: 78-3.87). CONCLUSIONS: The high frequency of poor sleep quality and metabolic decompensation in the sample stands out, which could complicate DM2. The association between poor sleep quality and DM2 decompensation is inconclusive. Future research will contribute to elucidating the role of sleep in metabolic compensation and in the prevention of metabolic disorders.

Calidad del sueño en personas con diabetes tipo 2 controladas en el nivel primario y su asociación con características sociodemográficas y clínicas / Sleep quality in people with type 2 diabetes controlled at the primary level and its association with sociodemographic and clinical characteristics

La diabetes tipo 2 (DM2) es una de las enfermedades que causa mayor mortalidad prematura y discapacidad a nivel mundial. Las alteraciones del sueño se han asociado a la aparición de trastornos metabólicos y a mayores niveles de hemoglobina glucosilada en personas diabéticas.Objetivo:Evaluar la calidad del sueño de personas con DM2 y su asociación con características sociodemográficas, clínicas y metabólicas.Métodos:Estudio observacional, transversal, analítico en 223 personas con DM2 entre 20 y 64 años controladas en un centro de atención primaria de salud.Resultados:La mayoría eran mujeres (66,4%), edad promedio 54,7 años y solo el 33% duerme las horas necesarias (7 a 9 horas). Un 57,7% se encontraba metabólicamente descompensado (Hb1Ac>7%). Un 75,2% de los participantes presentó problemas de sueño de diversa gravedad, que se asoció a ser mujer, dolor nocturno, nicturia, tiempo de diagnóstico de la diabetes y síntomas depresivos. Las personas con mala calidad de sueño tuvieron 73% más probabilidad de estar descompensados metabólicamente, sin embargo, este resultado no fue estadísticamente significativo OR=1,73 (IC: 0,78-3,87).Conclusiones:Destaca la alta frecuencia de mala calidad de sueño y descompensación metabólica en la muestra, lo que podría complicar la DM2. No es concluyente la asociación entre mala calidad de sueño y descompensación de la DM2. Futuras investigaciones contribuirán a dilucidar el papel del sueño en la compensación metabólica y en la prevención de trastornos metabólicos.

Type 2 diabetes (DM2) is one of the diseases that cause the highest premature mortality and disability worldwide. Sleep disturbances have been associated with the onset of metabolic disorders and increased levels of glycated haemoglobin in diabetics.Objective:To evaluate the quality of sleep of people with type 2 diabetes and its association with sociodemographic, clinical, and metabolic characteristics.Methods:Observational, cross-sectional, analytical study of 223 patients with DM2 between 20 and 64 years old, controlled in a primary health care centre in Chile.Results:Most were women (66.4%), average age 54.7 years. Only 33% slept the required number of hours (7 to 9hours) to maintain health. Fifty-seven point seven percent were metabolically unbalanced (Hb1Ac>7%). Seventy-five point two percent presented sleep problems of varying severity, which were associated with being a woman, night pain, nocturia, time of diagnosis of diabetes, and depressive symptoms. Persons with poor sleep quality were 73% more likely to be metabolically decompensated, however, this result was not statistically significant: OR=1.73 (CI:78-3.87).Conclusions:The high frequency of poor sleep quality and metabolic decompensation in the sample stands out, which could complicate DM2. The association between poor sleep quality and DM2 decompensation is inconclusive. Future research will contribute to elucidating the role of sleep in metabolic compensation and in the prevention of metabolic disorders.

The calculated versus the measured glycosylated haemoglobin (HbA1c ) levels in patients with type 2 diabetes mellitus.

BACKGROUND: Diabetes mellitus (DM) is a chronic metabolic disorder that is increasing globally. It is associated with chronic complications that are more common among patients with poor glycaemic control. Glycosylated haemoglobin (HbA1c ) is the gold standard for monitoring glycaemic control. Measurements of HbA1c are relatively expensive and not available in some remote areas of developing countries. METHODS: We conducted a cross-sectional study to evaluate the agreement between the calculated and measured HbA1c levels. The equation to compute the calculated HbA1c also incorporated the fasting blood glucose (FBG) level and was as follows: HbA1c  = 2.6 + 0.03 × FBG (mg/dl). RESULT: We enrolled 290 patients with type 2 DM in this study. Of these, 204 (70.3%) were females and the mean (SD) age was 54.9 (12.8) years. The mean (SD) diabetes duration was 6.8 (5.5) years. There were 211 (72.8%) patients using oral hypoglycaemic agents, 62 (21.4%) were using insulin and 17 (5.9%) were using both insulin and oral hypoglycaemic agents. There was a borderline difference between the mean (SD) calculated and measured HbA1c levels (p = 0.054). There was a significant correlation between the calculated and measured HbA1c (r = 0.595, p < 0.001). However, there was no agreement between the calculated and measured HbA1c . The bias ±SD (limits of agreement) for calculated versus measured HbA1c was -1.008 ± 2.02% (-5.05, 2.032). CONCLUSION: Despite the presence of a significant correlation between the calculated and measured HbA1c , the calculated level has shown an unacceptable agreement with the measured HbA1c .

Association between Walking Pace and Diabetes: Findings from the Chilean National Health Survey 2016-2017.

BACKGROUND: Walking pace is a well-known indicator of physical capability, but it is also a strong predictor of type 2 diabetes (T2D). However, there is a lack of evidence on the association between walking pace and T2D, specifically, within developing countries such as Chile. AIM: To investigate the association between self-reported walking pace and T2D in the Chilean adult population. METHODS: 5520 Chilean participants (aged 15 to 90 years, 52.1% women) from the Chilean National Health Survey 2016-2017 were included in this cross-sectional study. Both walking pace (slow, average, and brisk) and diabetes data were collected through self-reported methods. Fasting blood glucose (reported in mg/dl) and glycosylated haemoglobin A (HbA1c) scores were determined via blood exams. RESULTS: In the unadjusted model, and compared to people who reported a slow walking pace, those with average and brisk walking pace had lower blood glucose levels (ß = -7.74 mg/dL (95% CI: -11.08 to -4.40) and ß = -11.05 mg/dL (95% CI: -14.36 to -7.75), respectively) and lower HbA1c (ß = -0.34% (95% CI: -0.57 to -0.11) and ß= -0.72% (95% CI: -0.94 to -0.49)), respectively. After adjusting for sociodemographic, Body Mass Index and lifestyle factors, the association between glycaemia and HbA1c remained only for brisk walkers. Both the average and brisk walker categories had lower odds of T2D (OR: 0.59 (95% CI: 0.41 to 0.84) and (OR 0.48 (95% CI: 0.30 to 0.79), respectively). CONCLUSION: Brisk walkers were associated with lower blood glucose and HbA1c levels. Moreover, average to brisk walking pace also showed a lower risk for T2D.

A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial.

AIMS/HYPOTHESIS: This randomised controlled trial was performed in India and the UK in people with prediabetes to study whether mobile phone short message service (SMS) text messages can be used to motivate and educate people to follow lifestyle modifications, to prevent type 2 diabetes. METHODS: The study was performed in people with prediabetes (n = 2062; control: n = 1031; intervention: n = 1031) defined by HbA1c ≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4%). Participants were recruited from public and private sector organisations in India (men and women aged 35-55 years) and by the National Health Service (NHS) Health Checks programme in the UK (aged 40-74 years without pre-existing diabetes, cardiovascular disease or kidney disease). Allocation to the study groups was performed using a computer-generated sequence (1:1) in India and by stratified randomisation in permuted blocks in the UK. Investigators in both countries remained blinded throughout the study period. All participants received advice on a healthy lifestyle at baseline. The intervention group in addition received supportive text messages using mobile phone SMS messages 2-3 times per week. Participants were assessed at baseline and at 6, 12 and 24 months. The primary outcome was conversion to type 2 diabetes and secondary outcomes included anthropometry, biochemistry, dietary and physical activity changes, blood pressure and quality of life. RESULTS: At the 2 year follow-up (n = 2062; control: n = 1031; intervention: n = 1031), in the intention-to-treat population the HR for development of type 2 diabetes calculated using a discrete-time proportional hazards model was 0.89 (95% CI 0.74, 1.07; p = 0.22). There were no significant differences in the secondary outcomes. CONCLUSIONS/INTERPRETATION: This trial in two countries with varied ethnic and cultural backgrounds showed no significant reduction in the progression to diabetes in 2 years by lifestyle modification using SMS messaging. TRIAL REGISTRATION: The primary study was registered on www.ClinicalTrials.gov (India, NCT01570946; UK, NCT01795833). FUNDING: The study was funded jointly by the Indian Council for Medical Research and the UK Medical Research Council.

A randomised controlled trial of potential for pharmacologic prevention of new-onset albuminuria, hypertension and diabetes in a remote Aboriginal Australian community, 2008-2013.

INTRODUCTION: We conducted a double-blind randomised controlled trial in a remote-living Australian Aboriginal group at high risk for chronic disease to assess whether pharmacological treatment with angiotensin converting enzyme inhibitor (ACEi) could delay the onset of albuminuria, hypertension or diabetes in people currently free of those conditions. METHODS: Eligibility criteria in 2008 were age ≥18yr, blood pressure ≤140/90 mm/Hg, urinary albumin creatinine ratio (ACR) < 3.4 mg/mmol, normal levels of glycosylated haemoglobin, and, in females, infertility. A 2011 amendment allowed enrolment of fertile females using long-term contraception. "Treatment" was the ACEi perindopril arginine, or placebo, and participant events were ACR ≥3.4 mg/mmol and/or blood pressure >140/90 mm Hg and/or haemoglobin A1c >6.5%, and/or cardiovascular events. Results were analysed in 125 randomised participants who commenced treatment. RESULTS: Recruitment was low, especially of women, and dropout rates high: there were finally 60 and 65 people in the ACEi and placebo groups respectively. In females, there were no events among 10 in the ACEi group, versus 5 events among 17 in the placebo group, and longitudinal ACR, HbA1c and blood pressure levels supported probable benefit of ACEi. There was no benefit of ACEi in males, but a probable benefit on diabetes/hypertension events. With the genders combined, there was probable reduction of diabetes (zero vs 4 events, p = 0.068), and of diabetes or hypertension (zero vs 5 events, p = 0.037). DISCUSSION: In this high-risk population, ACEi probably delays development of albuminuria, diabetes and hypertension in females, and of non-ACR events overall. Repeat investigation with a larger sample size is warranted.

A simple to implement and low-cost supervised walking programme in highly motivated individuals with or at risk for type 2 diabetes: An observational study with a pre-post design.

This observational study with a pre-post design, conducted in two Dutch primary healthcare centres, aimed to evaluate the effect of a supervised walking programme in highly motivated individuals with or at risk for type 2 diabetes mellitus (T2DM). Those able and willing to walk at least 6 km, were invited for a 28-week walking programme (February to August 2017), in which participants walked in groups, once weekly under supervision of volunteer healthcare professionals. Changes in bodyweight, BMI, waist circumference, HbA1c, blood pressure, well-being, health status and patient activation were analysed using paired t-tests and the Wilcoxon signed-rank test. Fifty-six people were included (30 T2DM; 26 at risk), of whom 60.7% were female. Mean age was 60.6 years, median BMI 30.8 kg/m2 and mean systolic blood pressure 146.9 mm Hg. Participants with T2DM had median HbA1c of 50.0 mmol/mol. Post-challenge, BMI had decreased to 29.7 kg/m2, and waist circumference decreased 3.4 cm (95% CI 2.1-4.8), both p < 0.01. Systolic and diastolic blood pressure decreased significantly (mean difference 6.5 mm Hg (95% CI 1.6-11.3, p = 0.01) and 3.5 mm Hg (95% CI 1.0-6.0, p < 0.01), respectively). Participants with HbA1c >53 mmol/mol at baseline (n = 8), had median decrease in HbA1c of 6.5 mmol/mol (p = 0.03). Well-being, but not health status and patient activation, improved significantly. In conclusion, in highly motivated individuals with or at risk for T2DM, this simple to implement and low-cost, but intensive, volunteer-based supervised walking programme is favourable, and therefore, can be seen as an option for clinical programs to implement to support highly motivated patients.

HbA1c and hypoglycaemia in intensively treated type 2 diabetes: a retrospective cohort study in primary care.

OBJECTIVE: To establish whether low HbA1c is associated with clinical hypoglycaemia among people with type 2 diabetes prescribed insulins or sulphonylureas. DESIGN: Retrospective cohort study using routine electronic GP health records collected between January 2013 and December 2015. SETTING: Three east London Clinical Commissioning Groups. PARTICIPANTS: Two cohorts of adults with type 2 diabetes prescribed either (i) insulins with or without other oral antidiabetic medication (n = 6788, 36.4%) or (ii) sulphonylureas with or without other oral antidiabetic medications excluding insulins (n = 11,840, 63.6%). MAIN OUTCOME MEASURES: First clinically recorded hypoglycaemia and all-cause mortality. Hazard ratios (HR) adjusting for age, ethnicity, renal function and comorbidities were calculated using Cox regression models. RESULTS: Compared with an HbA1c of 53-63 mmol/mol, the adjusted HR of hypoglycaemia in those with a low HbA1c, below 53 mmol/mol, in the insulin and sulphonylurea cohorts were 1.26 (95% CI, 0.97 to 1.62) and 1.54 (95% CI, 1.27 to 1.87), respectively. Adjusted HRs of all-cause mortality from low HbA1c in the insulin and sulphonylurea cohorts were 1.54 (95% CI, 1.15 to 2.07) and 1.42 (95% CI, 1.11 to 1.81), respectively. Increasing age and renal impairment were also associated with increased hypoglycaemic risk in both cohorts. CONCLUSIONS: HbA1c below 53 mmol/mol was associated with episodes of clinical hypoglycaemia among people with type 2 diabetes prescribed sulphonylureas, and all-cause mortality in those prescribed insulins and sulphonylureas. These findings support the need for reviewing glycaemic targets and the intensities of treatment in those with low HbA1c prescribed insulins or sulphonylureas to reduce the risk of hypoglycaemia.

Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

AIMS: To analyse the effect of baseline glycated haemoglobin (HbA1c) on the reduction in HbA1c with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. MATERIALS AND METHODS: Using regression analyses of individual patient data from two Phase III studies, we compared the change in HbA1c according to a unit change in baseline HbA1c (the slope) with empagliflozin 10 mg or 25 mg vs sitagliptin (monotherapy) after 24 weeks, and with empagliflozin 25 mg vs glimepiride (as add-on to metformin) after 52 weeks. RESULTS: Steeper slopes of HbA1c decline were observed with empagliflozin 10 or 25 mg vs sitagliptin monotherapy at week 24. Regression analysis showed slopes of -0.59 (95% CI -0.70, -0.47), -0.49 (95% CI -0.62, -0.37) and -0.29 (95% CI -0.42, -0.15) for empagliflozin 10 mg, empagliflozin 25 mg and sitagliptin, respectively (P < .001 and P < .05 for empagliflozin 10 mg and empagliflozin 25 mg, respectively, vs sitagliptin). Similarly, a steeper slope of HbA1c decline was observed with empagliflozin 25 mg vs glimepiride as add-on to metformin at week 52. Regression analysis showed slopes of - 0.52 (95% CI -0.59, -0.44) and -0.32 (95% CI -0.39, -0.25) for empagliflozin 25 mg and glimepiride, respectively (P < .001 for empagliflozin 25 mg vs glimepiride). CONCLUSIONS: Incremental reductions in HbA1c with increasing baseline HbA1c are greater with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

Benefits of a Paleolithic diet with and without supervised exercise on fat mass, insulin sensitivity, and glycemic control: a randomized controlled trial in individuals with type 2 diabetes.

BACKGROUND: Means to reduce future risk for cardiovascular disease in subjects with type 2 diabetes are urgently needed. METHODS: Thirty-two patients with type 2 diabetes (age 59 ± 8 years) followed a Paleolithic diet for 12 weeks. Participants were randomized to either standard care exercise recommendations (PD) or 1-h supervised exercise sessions (aerobic exercise and resistance training) three times per week (PD-EX). RESULTS: For the within group analyses, fat mass decreased by 5.7 kg (IQR: -6.6, -4.1; p < 0.001) in the PD group and by 6.7 kg (-8.2, -5.3; p < 0.001) in the PD-EX group. Insulin sensitivity (HOMA-IR) improved by 45% in the PD (p < 0.001) and PD-EX (p < 0.001) groups. HbA1c decreased by 0.9% (-1.2, -0.6; p < 0.001) in the PD group and 1.1% (-1.7, -0.7; p < 0.01) in the PD-EX group. Leptin decreased by 62% (p < 0.001) in the PD group and 42% (p < 0.001) in the PD-EX group. Maximum oxygen uptake increased by 0.2 L/min (0.0, 0.3) in the PD-EX group, and remained unchanged in the PD group (p < 0.01 for the difference between intervention groups). Male participants decreased lean mass by 2.6 kg (-3.6, -1.3) in the PD group and by 1.2 kg (-1.3, 1.0) in the PD-EX group (p < 0.05 for the difference between intervention groups). CONCLUSIONS: A Paleolithic diet improves fat mass and metabolic balance including insulin sensitivity, glycemic control, and leptin in subjects with type 2 diabetes. Supervised exercise training may not enhance the effects on these outcomes, but preserves lean mass in men and increases cardiovascular fitness. Copyright © 2016 John Wiley & Sons, Ltd.

Associations of demographic and behavioural factors with glycaemic control in young adults with type 1 diabetes mellitus.

BACKGROUND: Despite recognised benefits of optimal glycaemic control in patients with type 1 diabetes mellitus (T1DM), good control is still difficult to achieve, particularly for adolescents and young adults. Recognition of factors that may assist early optimisation of glycaemic control is therefore important. AIMS: We explored associations of demographic, social and behavioural factors with glycosylated haemoglobin (HbA1c) levels in participants with T1DM aged 18-25 years. METHODS: A cross-sectional analysis was performed on young adults attending a dedicated multidisciplinary clinic at Fremantle Hospital, Western Australia from January to August 2014. RESULTS: Data from 93 participants were analysed. Mean age was 21.4 ± 2.3 years, and 39.8% of the cohort were female. Longer duration of diabetes was associated with higher HbA1c (r = 0.25, P = 0.04). Men had lower HbA1c than women (8.2 ± 1.6 vs 9.2 ± 2.0%, P = 0.01). Increased frequency of clinic attendance was associated with lower HbA1c (r = -0.27, P = 0.02). Those engaged in work or study had better HbA1c compared with those who were not (8.9 ± 2.1 vs 10.5 ± 2.1%, P = 0.03). Socioeconomic disadvantage, risk-taking behaviour, insulin pump use and distance travelled to clinic were not associated with differences in HbA1c. CONCLUSION: In young adults with T1DM, geographical separation, socioeconomic disadvantage and risk-taking behaviours did not influence glycaemic control. Longer duration of diabetes identifies young adults at higher risk of poor control, while attendance at a multidisciplinary clinic and engagement in work or study was associated with better glycaemic control. Additional studies are warranted to clarify the role of behavioural interventions to improve diabetes management in young adults.

[An analysis of the diabetic population in a Spanish rural are: morbidity profile, use of resources, complications and metabolic control]. / Análisis de la población diabética de una comarca: perfil de morbilidad, utilización de recursos, complicaciones y control metabólico.

OBJECTIVE: To describe the characteristics of a diabetic population, morbidity profile, resource consumption, complications and degree of metabolic control. DESIGN: Cross-sectional study during 2010. LOCATION: Four Health Areas (91.301 people) where the integrated management organization Serveis de Salut integrated Baix Empordà completely provide healthcare assistance. PARTICIPANTS: 4.985 diabetic individuals, identified through clinical codes using the ICD-9-MC classification and the 3M? Clinical Risk Groups software. MAIN MEASUREMENTS: Morbidity profile, related complications and degree of metabolic control were obtained for the target diabetic population. We analyzed the consumption of healthcare resources, pharmaceutical and blood glucose reagent strips. All measurements obtained at individual level. RESULTS: 99.3% of the diabetic population were attended at least once at a primary care center (14.9% of visits). 39.5% of primary care visits and less than 10% of the other scanned resources were related to the management of diabetes. The pharmaceutical expenditure was 25.4% of the population consumption (average cost ?1.014,57). 36.5% of diabetics consumed reagents strips (average cost ?120,65). The more frequent CRG are 5424-Diabetes (27%); 6144-Diabetes and Hypertension (25,5%) and 6143-Diabetes and Other Moderate Chronic Disease (17,2%). The degree of disease control is better in patients not consumers of antidiabetic drugs or treated with oral antidiabetic agents not secretagogues. CONCLUSIONS: Comorbidity is decisive in the consumption of resources. Just a few part of this consumption is specifically related to the management of diabetes. Results obtained provide a whole population approach to the main existing studies in our national and regional context.

Hemoglobina glicosilada A1c vs. glucemia plasmática en ayunas de pacientes ambulatorios de un laboratorio médico / Glycosylated haemoglobin A1c compared to fasting plasma glucose in outpatients referred to a medical laboratory

Objetivo Comparar la prueba hemoglobina glicosilada (HbA1c) en diferentes puntos de corte, con la prueba de glucemia plasmática en ayunas (GPA); para medición de glucosa en sangre en pacientes ambulatorios de un laboratorio médico de la ciudad de Medellín, entre marzo y abril de 2010. Métodos Estudio en 1016 muestras de sangre de pacientes referidos a un laboratorio médico. Se obtuvo la concordancia entre las pruebas (Índice de Kappa), se calcularon sensibilidad y especificidad, además se evaluaron diferentes puntos de corte para la prueba HbA1c con la curva ROC. Se usó correlación de Spearman para establecer la asociación entre GPA y HbA1c. Resultados El valor promedio de HbA1c fue 5,7 % ±0,8 y de la GPA fue 96 mg/dL±26,1; y esta última fue mayor en hombres (99,04±32,7). El 75,4 % de las muestras fueron normales para diagnóstico de diabetes con la prueba GPA, y con la HbA1c el 51,4 % clasificaron en este rango. El punto de corte donde la combinación sensibilidad-especificidad presenta los mejores valores para HbA1c fue 6,2 %. Discusión La prueba HbA1c presentó valores altos de sensibilidad y especificidad, por lo que su uso rutinario en el diagnóstico de diabetes mellitus podría contribuir a la búsqueda activa y la detección precoz de casos, que aseguren un mejor control de los factores de riesgo.

Objective Comparing haemoglobin A glycosylate (HbA1c) at different cutoff points for blood glucose measurement to the fasting plasma glucose (FPG) test in outpatients visiting a medical laboratory in the city of Medellin between March and April 2010. Methods 1,016 blood samples were studied from patients who had been referred to a medical laboratory. Agreement was obtained between tests (Kappa index); sensitivity and specificity were calculated. Different cutoff points for the HbA1c test were also evaluated with the ROC curve. Spearman correlation was used to establish association between FPG and Hb A1c. Results Average HbA1c was 5.7 %±0.8 and average FPG was 96 mg/dL±26.1; this was higher in men (99.04±32.7). 75.4 % of the samples came within the normal range for diagnosing diabetes with the FPG test, compared to 51.4 % with the HbA1c test. The cutoff point where combined sensitivity and specificity presented the best HbA1c value in this study group was 6.2 %. Discussion The HbA1c test had high sensitivity and specificity values, so its routine use in diagnosing diabetes mellitus could contribute towards active and early detection of cases to ensure better control of risk factors.

Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study.

OBJECTIVE: Insulin therapy is associated with weight gain in patients with type 2 diabetes mellitus (T2DM). Several peptides are implicated in appetite control. We evaluated the effects of insulin-induced improved glycaemic control on leptin, adiponectin, ghrelin, neuropeptide Y (NPY) levels and patient characteristics. METHOD: Consecutive T2DM patients (n = 90) were divided into 2 groups: Group A: 45 insulin-naïve uncontrolled (glycosylated haemoglobin A(1c); HbA(1c )>7%) patients on oral hypoglycaemic agents (OHAs) who converted to insulin monotherapy. Group B: 45 well-controlled (HbA(1c )<7%) patients on OHAs. Both groups were monitored at baseline, 3 and 6 months. Males and females were analyzed separately because some hormone levels differ between genders. RESULTS: In both genders, insulin therapy (Group A) was associated with significant (p = 0.003 to <0.001) increases in weight, body mass index and leptin levels and significant decreases in glucose, HbA(1c) and NPY levels. In male insulin-treated patients a significant increase in adiponectin levels (p = 0.008) was observed. There were significant correlations (p = 0.016 to <0.001) between leptin levels, waist circumference and body fat in all patient groups, except group B males. CONCLUSION: Changes in leptin, adiponectin and NPY levels may occur after insulin-induced improved glycaemic control. These changes may be influenced by gender, weight, body fat and HbA(1c).

Hemoglobina glucosilada A1C como parámetro de control metabólico en pacientes con diabetes mellitus / Glycated hemoglobin A1C as parameter metabolic control in patients with diabetes mellitus

Se realizó un estudio prospectivo , de carácter observacional ,para determinar los niveles de hemoglobina glicosilada A1c ( Hb A1c ) como parámetro de control metabólico en pacientes con diabetes mellitus del Hospital de Clínicas de La Paz,. Se seleccionó una muestra de 72 pacientes que contaban con controles periódicos de Hb A1C. De los mismos solo uno era diabético de tipo 1, el resto (71) son diabéticos tipo 2. El 69% (49) de los pacientes eran mujeres y un 31 % (23) varones. La mayor parte de los pacientes están por encima de los 45 años, dato en relación con el tipo de diabetes que se presenta (DMT2), el único caso de diabetes mellitus tipo 1 se da en un paciente menor de 25 años. Dos tercios de los pacientes (69% del total) no cuentan siquiera con una dosificación inicial de HbA1c. Se solicitó el examen al 75 % de los pacientes, solamente el 32,7% de los pacientes lo efectivizaron. El 43,3% de los pacientes que cuentan con el control presentaban un nivel de Hb A1c por debajo de 7,5%, sin embargo solo el 20 % logran la meta de Hb A1c por debajo de 6,5 %, que es la cifra que ha demostrado reducir las complicaciones crónicas de la diabetes. Se debe solicitar en la totalidad de los pacientes la dosificación de Hb A1c (como mínimo tres veces al año) para permitirnos conocer la efectividad del manejo realizado y lograr la prevención de complicaciones crónicas.

This is a prospective observational study in order to determine the levels of glycosylated hemoglobin A1c (HbA1c) as parameter of metabolic control in patients with diabetes mellitus in the Hospital de Clinicas, La Paz. A sample of 72 patients was selected who had periodic controls of HbA1c. Only one of these patients had diabetes type 1, the rest (71) had diabetes type 2. Of the patients, 49 (69%) were females and 23 (31%) were males. The majority of the patients were older than 45 years, which is to be expected in relation with the type of diabetes presented (DMT2), being the only case of diabetes type 1 a man under 25 years of age. Two thirds of the patients (69% of the total) did not even have an initial measurement of HbA1c. This measurement was requested in 75% of the patients, but only 32.7% had the test done. The 43.3% of the patients who had the control, showed a level of HbA1c below 7.5%, however, only 20% achieved the goal of a HbA1c below 6.5%, which is the level that has been shown to reduce the chronic complications of diabetes. In all patients a periodic control of HbA1c should be requested at least 3 times per year, in order to know the effectiveness of our work and to prevent chronic complications of diabetes.